Systemic sclerosis and risk of venous thromboembolism: A systematic review and meta-analysis

Modern Rheumatology

Volumn 25, Issue 6, 2015, Pages 893-897

  Ungprasert, Patompong ^a,b   Srivali, Narat ^c   Kittanamongkolchai, Wonngarm ^c  

^a Mayo Clinic College of Medicine   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

^c MAYO CLINIC   (United States)

Author keywords

Epidemiology; Meta analysis; Scleroderma; Systemic sclerosis; Venous thromboembolism

Indexed keywords

ARTICLE; DATA EXTRACTION; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PUBLICATION; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; SYSTEMIC SCLEROSIS; VENOUS THROMBOEMBOLISM;

EID: 84946830590     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2015.1038456     Document Type: Article

References (31)

1. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous thrombosis: A population-based study. J Thromb Haemost. 2007;5(4):692-9.
2. Cushman M, Tsai AW, White RH, Heckbert SR, Rosamond WD, Enright P, Folsom AR. Deep venous thrombosis and pulmonary embolism in two cohorts: The longitudinal investigation of thromboembolism etiology. Am J Med. 2004;117(1):19-25.
3. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Predictor of survival after deep venous thrombosis and pulmonary embolism: A population-based, cohort study. Arch Intern Med. 1999;159(5):445-53.
4. Hawbaker S. Venous thromboembolism in the cancer population: Pathology, risk, and prevention. J Adv Pract Oncol. 2012;3(1):23-33.
5. Ungprasert P, Srivali N, Wijarnpreecha K, Charoenpong P, Knight EL. Non-steroidal anti-inflammatory drugs and risk of venous thromboembolism: A systematic review and meta-analysis. Rheumatology (Oxford). 2014;55(4);736-42
6. Yusuf HR, Hooper WC, Grosse SD, Parker CS, Boulet SL, Ortel TL. Risk of venous thromboembolism occurrence among adults with selected autoimmune diseases: A study among a U.S. cohort of commercial insurance enrollees. Thromb Res. 2015;135(1):50-7.
7. Ungprasert P, Sanguankeo A. Risk of venous thromboembolism in patients with idiopathic inflammatory myositis: a systematic review and meta-analysis. Rheumatol Int. 2014;34(10):1455-8.
8. Ungprasert P, Sanguankeo A, Upala S, Suksaranjit P. Psoriasis and risk of venous thromboembolism: A systematic review and meta-analysis. QJM. 2014;107(10):793-7.
9. Tomasson G, Monach PA, Merkel PA. Thromboembolic disease in vasculitis. Curr Opin Rheumatol. 2009;21(1):41-6.
10. Ungprasert P, Srivali N, Spanuchart I, Thongprayoon C, Knight EL. Risk of venous thromboembolism in patients with rheumatoid arthritis: A systematic review and meta-analysis. Clin Rheumatol. 2014;33(3):297-304.
11. Almeida I, Faria R, Vita P, Vasconcelos C. Systemic sclerosis refractory disease: from the skin to the heart. Autoimmun Rev. 2011;10(11):693-701.
12. Wells AU, Margaritopoulos GA, Antoniou KM, Denton C. Interstitial lung disease in systemic sclerosis. Semin Respir Crit Care Med. 2014;35(2):213-21.
13. Ungprasert P, Charoenpong P, Ratanasrimetha P, Thongprayoon C, Cheungpasitporn W, Suksaranjit P. Risk of coronary artery disease in patients with systemic sclerosis: A systematic review and meta-analysis. Clin Rheumatol. 2014;33(8):1099-104.
14. Ramagopalan SV, Wotton CJ, Handel AE, Yeates D, Goldacre MJ. Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study. BMC Medicine. 2011;9:1.
15. Johannesdottir SA, Schmidt M, horvath-Puho E, Sørensen HT. Autoimmune skin and connective tissue diseases and risk of venous thromboembolism: a population-based case-control study. J thromb haemost. 2012;10(5):815-21.
16. Zoller B, Li X, Sunquist J, Sunquist K. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet. 2012;379(9812):244-9.
17. Avina-Zubieta JA, Hemmati I, Sayre EC, et al. The risk of pulmonary embolism and deep vein thrombosis in systemic sclerosis: A population based study. Presented at the American college of rheumatology annual scientific meeting. 25-30 October 2013, San Diego, California. [Abstract number 1814].
18. Chung WS, Lin CL, Sung FC, Hsu WH, Yang WT, Lu CC, Kao CH Systemic sclerosis increases the risks of deep vein thrombosis and pulmonary thromboembolism: A nationwide cohort study. Rheumatology (Oxford). 2014;53(9):1639-45.
19. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603-5.
20. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trial. 1986;7(3):177-88.
21. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-60.
22. Hashimoto A, Tejima S, Tono T, Suzuki M, Tanaka S, Matsui T, et al. Predictors of survival and causes of death in Japanese patients with systemic sclerosis. J Rheumatol. 2011;38(9):1931-9.
23. Gupta R, Thaba MM, Gupta S, Shankar S, Kumar A. Clinical significance of antiphospholipid antibodies in Indian scleroderma patients. Rheumatol Int. 2009;30(2):277-9.
24. Sanna G, Bertolaccini ML, Mameli A, Hughes G, Khamashta M, Mathieu A. Antiphospholipid antibodies in patients with scleroderma: Prevalence and clinical significance. Ann Rheum Dis. 2005;64(12):1795-6.
25. Xu J, Lupu F, Esmon CT. Inflammation, innate immunity and blood coagulation. Hamostaseologie. 2010;30(1):5-6, 8-9.
26. Nagareddy P, Smyth SS. Inflammation and thrombosis in cardiovascular disease. Curr Opin Hematol. 2013;20(5):457-63.
27. Silvarino R, Danza A, Merola V, Berez A, Mendez E, Espinosa G, Cervera R. Venous thromboembolic disease in systemic autoimmune diseases: An association to keep in mind. Autoimmune Rev. 2012;12(2):289-94.
28. Montecucco F, Mach F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology (Oxford). 2009;48(1):11-22.
29. Biasillio G, Leo M, Della Bona R, Marzio Biasucci L. Inflammatory bio-marker and coronary artery disease: from bench to bedside and back. Intern Emerg Med. 2010;5(3):225-33.
30. Jezovnik MK, Poredos P. Idiopathic venous thrombosis is related to systemic inflammatory response and to increased levels of circulating markers of endothelial dysfunction. Int Angiol. 2010;29(3):226-31.
31. Ungprasert P, Sanguankeo A, Upala S, Knight EL. Risk of malignancy in patients with giant cell arteritis and polymyalgia rheumatica: A systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44(3):366-70.